- Home
- / Cynata Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cynata Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-04
Market Capitalization
$49.7 M
2024-10-04
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| AUD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.0K | |||||||
| Gross profit | 1.4M | 1.4M | 7.2M | 1.6M | 7.8M | 1.7M | 2.3M | 1.9M |
| Gross profit margin, % | 10839.4% | |||||||
| Operating expense total | 5.9M | 9.8M | 10.0M | 8.8M | 13.6M | 16.3M | 12.3M | 11.2M |
| Depreciation and amortization | 279.0K | 280.0K | 281.0K | 280.0K | 280.0K | 280.0K | 281.0K | 283.0K |
| EBITDA | (4.5M) | (8.4M) | (2.9M) | (7.2M) | (5.8M) | (14.6M) | (9.9M) | (9.3M) |
| EBITDA margin, % | -4325.8% | |||||||
| EBIT | (4.8M) | (8.7M) | (3.1M) | (7.5M) | (6.1M) | (14.9M) | (10.2M) | (9.6M) |
| EBIT margin, % | -4751.5% | |||||||
| Interest income | 143.0K | 195.0K | 93.0K | 64.0K | 353.0K | 418.0K | 228.0K | |
| Pre tax profit | (4.6M) | (8.5M) | (3.6M) | (7.7M) | (5.4M) | (14.3M) | (9.7M) | (9.4M) |
| Net Income | (4.6M) | (8.5M) | (3.6M) | (7.7M) | (5.4M) | (14.3M) | (9.7M) | (9.4M) |